A pilot study of angiogenin in heart failure with preserved ejection fraction: A novel potential biomarker for diagnosis and prognosis?

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 11, 2014, Pages 2189-2197

  Jiang, Hong ^a   Zhang, Lei ^a   Yu, Ying ^a   Liu, Ming ^a   Jin, Xuejuan ^a   Zhang, Peipei ^a   Yu, Peng ^a   Zhang, Shuning ^a   Zhu, Hongmin ^a   Chen, Ruizhen ^a   Zou, Yunzeng ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Angiogenin; Biomarker; Heart failure with preserved ejection fraction; Proteomics

Indexed keywords

ANGIOGENIN; BIOLOGICAL MARKER; PANCREATIC RIBONUCLEASE;

ADULT; AGED; BIOSYNTHESIS; BLOOD; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PILOT STUDY; PROGNOSIS;

ADULT; AGED; BIOMARKERS; FEMALE; GENE EXPRESSION REGULATION; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; RIBONUCLEASE, PANCREATIC; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 84911433736     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12344     Document Type: Article

References (36)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013; 127: e6-245.
2. Curtis LH, Whellan DJ, Hammill BG, et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med. 2008; 168: 418-24.
3. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292: 344-50.
4. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002; 347: 1397-402.
5. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012; 126: 65-75.
6. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006; 355: 251-9.
7. Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. JAMA. 2006; 296: 2209-16.
8. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128: e240-319.
9. Punnoose LR, Givertz MM, Lewis EF, et al. Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail. 2011; 17: 527-32.
10. Adamopoulos S, Parissis JT, Kremastinos DT. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail. 2001; 3: 517-26.
11. Tello-Montoliu A, Patel JV, Lip GY. Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost. 2006; 4: 1864-74.
12. Tello-Montoliu A, Marin F, Patel J, et al. Plasma angiogenin levels in acute coronary syndromes: implications for prognosis. Eur Heart J. 2007; 28: 3006-11.
13. Krecki R, Krzeminska-Pakula M, Drozdz J, et al. Relationship of serum angiogenin, adiponectin and resistin levels with biochemical risk factors and the angiographic severity of three-vessel coronary disease. Cardiol J. 2010; 17: 599-606.
14. Eleuteri E, Di Stefano A, Tarro Genta F, et al. Stepwise increase of angiopoietin-2 serum levels is related to haemodynamic and functional impairment in stable chronic heart failure. Eur J Cardiovasc Prev Rehabil. 2011; 18: 607-14.
15. Link A, Poss J, Rbah R, et al. Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. Eur Heart J. 2013; 34: 1651-62.
16. Patel JV, Abraheem A, Chackathayil J, et al. Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction amongst patients with coronary artery disease. J Intern Med. 2009; 265: 562-7.
17. Patel JV, Sosin M, Gunarathne A, et al. Elevated angiogenin levels in chronic heart failure. Ann Med. 2008; 40: 474-9.
18. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008; 10: 933-89.
19. Piran S, Liu P, Morales A, et al. Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure. J Am Coll Cardiol. 2012; 60: 283-9.
20. Mebazaa A, Vanpoucke G, Thomas G, et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J. 2012; 33: 2317-24.
21. Watson CJ, Ledwidge MT, Phelan D, et al. Proteomic analysis of coronary sinus serum reveals leucine-rich alpha2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure. Circ Heart Fail. 2011; 4: 188-97.
22. Dubois E, Fertin M, Burdese J, et al. Cardiovascular proteomics: translational studies to develop novel biomarkers in heart failure and left ventricular remodeling. Proteomics Clin Appl. 2011; 5: 57-66.
23. Arrell DK, Zlatkovic Lindor J, Yamada S, et al. K(ATP) channel-dependent metaboproteome decoded: systems approaches to heart failure prediction, diagnosis, and therapy. Cardiovasc Res. 2011; 90: 258-66.
24. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S. Clinical characteristics and outcomes of heart failure with preserved ejection fraction: lessons from epidemiological studies. J Cardiol. 2010; 55: 13-22.
25. Brouwers FP, de Boer RA, van der Harst P, et al. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J. 2013; 34: 1424-31.
26. Bhuiyan T, Maurer MS. Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep. 2011; 5: 440-9.
27. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009; 119: 3070-7.
28. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1787-847.
29. Lainscak M, Anker SD. Prognostic factors in chronic heart failure. A review of serum biomarkers, metabolic changes, symptoms, and scoring systems. Herz. 2009; 34: 141-7.
30. Eleftheriadis T, Antoniadi G, Liakopoulos V, et al. Plasma angiogenin and vascular endothelial growth factor a among hemodialysis patients. Iran J Kidney Dis. 2012; 6: 209-15.
31. Gui C, Li SK, Nong QL, et al. Changes of serum angiogenic factors concentrations in patients with diabetes and unstable angina pectoris. Cardiovasc Diabetol. 2013; 12: 34.
32. Anand IS, Rector TS, Cleland JG, et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial. Circ Heart Fail. 2011; 4: 569-77.
33. McKelvie RS, Komajda M, McMurray J, et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. J Card Fail. 2010; 16: 128-34.
34. Kraigher-Krainer E, Shah AM, Gupta DK, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014; 63: 447-56.
35. Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail. 2010; 12: 1339-44.
36. Cleland JG, Taylor J, Freemantle N, et al. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail. 2012; 14: 487-94.